Sevoflurane preconditioning ameliorates traumatic spinal cord injury through caveolin-3-dependent cyclooxygenase-2 inhibition

Weidong Wu; Ningxian Wei; Lihui Wang; Danhui Kong; Gang Shao; Yingchun Qin; Lixin Wang; Yansheng Du

doi:10.18632/oncotarget.21142

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Sevoflurane preconditioning ameliorates traumatic spinal cord injury through caveolin-3-dependent cyclooxygenase-2 inhibition

Weidong Wu _, Ningxian Wei, Lihui Wang, Danhui Kong, Gang Shao, Yingchun Qin, Lixin Wang and Yansheng Du

PDF | HTML | How to cite

Oncotarget. 2017; 8:87658-87666. https://doi.org/10.18632/oncotarget.21142

Metrics: PDF 1371 views | HTML 2160 views | ?

Abstract

Weidong Wu1,*, Ningxian Wei1,*, Lihui Wang1,*, Danhui Kong1, Gang Shao1, Yingchun Qin1, Lixin Wang2 and Yansheng Du3

1Danyang People’s Hospital of Jiangsu Province, Danyang, Jiangsu, PR China

2School of Medicine, Southeast University, Nanjing, Jiangsu, PR China

3School of Medicine, Indiana University, Indianapolis, Indiana, United States

*These authors have contributed equally to this work

Correspondence to:

Weidong Wu, email: [email protected]

Keywords: sevoflurane preconditioning, traumatic spinal cord injury, COX-2, Cav-3, anaesthesia

Received: March 21, 2017 Accepted: August 26, 2017 Published: September 21, 2017

ABSTRACT

Acute traumatic spinal cord injury (tSCI) results in a lifetime of paralysis associated with a host of medical complications. The developing secondary complications of tSCI may result in further chronic neurodegenerative diseases. Sevoflurane preconditioning (SF-PreCon) has shown guaranteed protective effects in myocardial or cerebral ischemic/reperfusion injury. However, the role of SF-PreCon in tSCI still remains to be elucidated. Here, we found that SF-PreCon ameliorated the developing secondary complications through reducing the apoptosis rate and the secretion of inflammatory cytokines in injured spinal cord tissues, and therefore enhancing the recovery after tSCI. Notably, we demonstrated that SF-PreCon ameliorates tSCI through inhibiting Cycloxygenase-2 (COX-2). Importantly, we verified that SF-PreCon inhibits the expression of COX-2 and reduces the apoptosis rate after tSCI via the induction of Caveolin-3 (Cav-3). Taken together, our results suggest that SF-PreCon ameliorates tSCI via Cav-3-dependent COX-2 inhibition and provide an economical and practical method against the secondary injury after tSCI.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21142

Publication Alerts

Research Papers:

Sevoflurane preconditioning ameliorates traumatic spinal cord injury through caveolin-3-dependent cyclooxygenase-2 inhibition

Abstract